Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.
Home Search
Parkinson’s disease - search results
If you're not happy with the results, please do another search
Time for a change of tack on drug development for neurodegenerative diseases?
UCB's Duncan McHale outlines why reclassification might be a good idea to boost drug development for neurodegenerative diseases like Alzheimer's and Parkinson's
Neurodegenerative diseases are a growing global challenge, as medical advances ensure more individuals live longer. By 2020 there will be more than 40 million people in the world...
Positive progress for people with Parkinson’s
The European Parkinson’s Disease Association (EPDA) provide an update about the positive progress being made for people with Parkinson’s
My PD Journey is a multi-stakeholder European coalition led by the European Parkinson’s Disease Association (EPDA) and it is a positive development in terms of the positive progress being made for...
Treatments and symptoms of Parkinson’s
Prof. David Dexter, deputy director of research at Parkinson’s UK shares his thoughts on the symptoms of Parkinson’s and the chances of finding a cure
The symptoms of Huntington’s disease
Chief Executive of the Huntington’s disease Association, Cath Stanley explores the symptoms, causes, and the vital role of research within the field
Can a new light-based therapy help with Alzheimer’s disease?
Prof Michael R Hamblin of the Wellman Center for Photomedicine at Massachusetts General Hospital discusses a new light-based therapy for Alzheimer’s disease
Drug development for neurodegenerative diseases
Professor Duncan McHale, Head Global Exploratory Development at UCB discusses the challenge of developing drugs to treat neurodegenerative diseases
What’s new in Parkinson’s rating scales?
Parkinson’s rating scales are a vital assessment tool, but have their limitations. Jennifer Stratten explains how and why the EPDA developed a new one
World Parkinson’s Day: uniting to raise awareness
Today, stakeholders from across the globe will unite to raise awareness of Parkinson’s during a dedicated campaign
The role of physiotherapy for Parkinson’s
Writing on behalf of the Chartered Society of Physiotherapy, Dr. Bhanu Ramaswamy highlights how physiotherapy can help manage the symptoms of Parkinson’s
Restoring dopaminergic nerve cells in Parkinson’s disease
Dr Mehis Pilv, CEO and business development lead at Genecode, discusses the strides being made in Parkinson's disease research
Parkinson's disease is a slow but progressive neurodegenerative disorder. About 1% of people aged above 50 are affected worldwide. In Europe alone 1.2 million people suffer from Parkinson's disease, 127,000 of whom...
Time for a change of tack on drug development for neurodegenerative diseases?
UCB's Duncan McHale outlines why reclassification might be a good idea to boost drug development for neurodegenerative diseases like Alzheimer's and Parkinson's
Neurodegenerative diseases are a growing global challenge, as medical advances ensure more individuals live longer. By 2020 there will be more than 40 million people in the world...
Better tailored care for people with Parkinson’s
My PD Journey – a project from the European Parkinson’s Disease Association (EPDA) looks at how challenges need to be tackled better at a European level in order to drive changes and improve diagnosis
On the occasion of Parkinson’s Awareness Month in April 2016, President of the European Parkinson’s Disease...
Brain disorders and the burden of diseases
Frédéric Destrebecq, Executive Director, and Vinciane Quoidbach, Public Health and Policy Project Manager at the European Brain Council, explain the socio-economic impact of interventions and the importance of early diagnosis with regard to brain disorders…
Depression, stroke, dementia, alcohol dependence, schizophrenia or anxiety will affect at least one in three...
Neurodegenerative diseases
Neurodegenerative diseases are a growing global challenge as medical advances ensures more individuals live longer. By 2020 there will be more than 40 million individuals in the world with Alzheimer’s disease and by 2040, without the development of truly disease modifying drugs this will be more than 80 million.
Reclassifying neurodegenerative diseases for drug development
Professor Duncan McHale, Head Global Exploratory Development, UCB discusses reclassifying neurodegenerative diseases to enable drug development and to help patients...
Neurodegenerative diseases are a growing global challenge as medical advances ensures more individuals live longer. By 2020 there will be more than 40 million individuals in the world with Alzheimer’s disease and...
Enabling research into Neurodegenerative disease through sharing of data
Professor Duncan McHale discusses neurodegenerative disease research...
Neurodegenerative diseases are a growing global challenge as medical advances ensures more individuals live longer. By 2020 there will be > 40 million individuals in the world with Alzheimer’s disease and by 2040 without the development of truly disease modifying drugs this will...
Nanoimaging to cure Alzheimer’s disease
Background of Alzheimer’s disease
Alzheimer’s disease (AD) is one of the most devastating neurodegenerative disorders affecting more than 25 million people worldwide which is the fifth leading cause of death for those aged 65 years and above. The disease typically starts with a difficulty to remember new information and as...
A stem cell solution for Parkinson’s?
Claire Bale, Communications Manager for Parkinson’s UK, highlights the latest thinking in stem cell research for the potential treatment of Parkinson’s.
Stem cells can develop into almost any cell in the body. They are the original cells from which we are made, and are responsible for repairing our tissues and...
The Personal Kinetigraph: The clinical and economic value of wearable digital technology in the...
In an interview with Clair Mace, examined what the Personal KinetiGraph can really do for patients dealing with Parkinson’s disease.
Parkinson’s drug pramipexole treats resistant depression, Oxford study finds
Oxford study finds Parkinson's drug pramipexole effective for treatment-resistant depression, with benefits lasting up to a year.
